ArticleMycoses2022
Emergence of Candida auris in intensive care units in Algeria.
Article in Mycoses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Global prevalence, mortality, and comorbidities of patients with diabetes mellitus and proven Candida auris emerging infection: a systematic review & meta-analysis.BMC infectious diseases · 2026Pooled it
- Review
- A Cross-Sectional Study to DetermineBioMed research international · 2026Article
- Diagnostic Approaches forMicroorganisms · 2025Review
- Seaside to Bedside: Assembly in Research for Emerging Human Fungal Pathogen Candida auris.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Review
- Potential Environmental Reservoirs ofJournal of fungi (Basel, Switzerland) · 2024Review
- Current global status of Candida auris an emerging multidrug-resistant fungal pathogen: bibliometric analysis and network visualization.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- The Nairobi Declaration 2023: A commitment to address deadly yet neglected fungal diseases in Africa.Medical mycology · 2024Article
- Emergence ofSAGE open medical case reports · 2024Article
- An Autochthonous SusceptibleJournal of fungi (Basel, Switzerland) · 2023Article
- Increasing Number of Cases Due toJournal of clinical medicine · 2023Article
- Fast and Accurate Identification ofJournal of fungi (Basel, Switzerland) · 2023Article
- Optimization and Validation of Candida auris Short Tandem Repeat Analysis.Microbiology spectrum · 2022Article
- Emergence and Genomic Characterization of Multidrug ResistantJournal of fungi (Basel, Switzerland) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundCurrently, Candida auris is among the most serious emerging pathogens that can be associated with nosocomial infections and outbreaks in intensive care units. Clinicians must be able to identify and manage it quickly.
objectiveHere, we report for the first time in Algeria seven cases of C. auris infection or colonisation. METHODS AND
resultsThe strains were isolated from clinical sites including bronchial aspirates (n = 4), wound swabs (n = 1), urine sample (n = 1) and peritoneal fluid (n = 1), in patients admitted to the intensive care unit. Candida auris was identified both by MALDI-TOF and by sequencing the ITS region and the D1/D2 domain. Antifungal susceptibility testing was performed using the E-test method. Non-wildtype susceptibility was observed for five strains against fluconazole, itraconazole, voriconazole and caspofungin. Genotyping showed the presence of four clades (I-IV) in one hospital.
conclusionsAppropriate antifungal treatments with rapid and accurate microbial identification are the cornerstone for the management and control of C. auris infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.